Pembrolizumab/MK-7684 or MK-4830 or MK-5890 or MK-0482

Biodrugs/ Drugs
KEYMAKER-U01 Master study: A phase 2, Umbrella study with Rolling Arms of Investigational Agents with either Pembrolizumab in combination with Chemotherapy or with Pembrolizumab alone in Patients with Advanced Non-small cell lung cancer (NSCLC)
2Phase II in Spain, 1Phase I